诺和诺德(NVO.US)计划为高剂量Wegovy申请美国监管批准

Group 1 - Novo Nordisk plans to apply for U.S. regulatory approval for a high-dose version of its weight loss therapy "Wegovy," aiming to compete against Eli Lilly's Zepbound in the growing obesity treatment market [1] - The company's Chief Scientific Officer, Martin Holst Lange, stated that the high-dose Wegovy has comparable weight loss potential to Eli Lilly's offering, providing new treatment options for patients [1] - Novo Nordisk is building a diversified product portfolio around the active ingredient semaglutide, which includes both high-dose injections and an oral tablet version of Wegovy [1] Group 2 - Earlier this year, Novo Nordisk submitted an application for the high-dose Wegovy in Europe [2] - The company reiterated plans to conduct late-stage clinical trials for the experimental compound cagrilintide, which operates through a different mechanism than semaglutide [2] - Novo Nordisk is adjusting its R&D strategy following underwhelming results from its next-generation obesity therapy CagriSema, planning to test cagrilintide's efficacy separately and optimize CagriSema's positioning through new clinical trials [2]